Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.
Tarih
2011Yazar
Hansen, S.
De Bono, J. S.
Ozguroglu, M.
Machiels, J. H.
Shen, L.
Sartor, A. O.
Oudard, S.
Üst veri
Tüm öğe kaydını gösterBağlantı
http://hdl.handle.net/20.500.12627/107294https://doi.org/10.1200/jco.2011.29.15_suppl.4525
Koleksiyonlar
- Makale [92796]